<?xml version='1.0' encoding='utf-8'?>
<document id="30990905"><sentence text="Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil."><entity charOffset="85-97" id="DDI-PubMed.30990905.s1.e0" text="Cyclosporine" /><entity charOffset="99-109" id="DDI-PubMed.30990905.s1.e1" text="Tacrolimus" /><entity charOffset="111-120" id="DDI-PubMed.30990905.s1.e2" text="Sirolimus" /><entity charOffset="126-147" id="DDI-PubMed.30990905.s1.e3" text="Mycophenolate Mofetil" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e0" e2="DDI-PubMed.30990905.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e0" e2="DDI-PubMed.30990905.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e0" e2="DDI-PubMed.30990905.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e0" e2="DDI-PubMed.30990905.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e1" e2="DDI-PubMed.30990905.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e1" e2="DDI-PubMed.30990905.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e1" e2="DDI-PubMed.30990905.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e2" e2="DDI-PubMed.30990905.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s1.e2" e2="DDI-PubMed.30990905.s1.e3" /></sentence><sentence text="Letermovir (AIC246, MK-8228) is a human cytomegalovirus terminase inhibitor indicated for the prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant recipients that is also being investigated for use in other transplant settings"><entity charOffset="0-10" id="DDI-PubMed.30990905.s2.e0" text="Letermovir" /></sentence><sentence text=" Many transplant patients receive immunosuppressant drugs, of which several have narrow therapeutic ranges" /><sentence text=" There is a potential for the coadministration of letermovir with these agents, and any potential effect on their pharmacokinetics (PK) must be understood" /><sentence text=" Five phase 1 trials were conducted in 73 healthy female participants to evaluate the effect of letermovir on the PK of cyclosporine, tacrolimus, sirolimus, and mycophenolic acid (active metabolite of mycophenolate mofetil [MMF]), as well as the effect of cyclosporine and MMF on letermovir PK"><entity charOffset="120-132" id="DDI-PubMed.30990905.s5.e0" text="cyclosporine" /><entity charOffset="134-144" id="DDI-PubMed.30990905.s5.e1" text="tacrolimus" /><entity charOffset="146-155" id="DDI-PubMed.30990905.s5.e2" text="sirolimus" /><entity charOffset="161-178" id="DDI-PubMed.30990905.s5.e3" text="mycophenolic acid" /><entity charOffset="201-222" id="DDI-PubMed.30990905.s5.e4" text="mycophenolate mofetil" /><entity charOffset="256-268" id="DDI-PubMed.30990905.s5.e5" text="cyclosporine" /><entity charOffset="273-276" id="DDI-PubMed.30990905.s5.e6" text="MMF" /><entity charOffset="224-226" id="DDI-PubMed.30990905.s5.e7" text="MMF" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e7" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e0" e2="DDI-PubMed.30990905.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e7" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e1" e2="DDI-PubMed.30990905.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e2" e2="DDI-PubMed.30990905.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e2" e2="DDI-PubMed.30990905.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e2" e2="DDI-PubMed.30990905.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e2" e2="DDI-PubMed.30990905.s5.e7" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e2" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e2" e2="DDI-PubMed.30990905.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e3" e2="DDI-PubMed.30990905.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e3" e2="DDI-PubMed.30990905.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e3" e2="DDI-PubMed.30990905.s5.e7" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e3" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e3" e2="DDI-PubMed.30990905.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e4" e2="DDI-PubMed.30990905.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e4" e2="DDI-PubMed.30990905.s5.e7" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e4" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e4" e2="DDI-PubMed.30990905.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e7" e2="DDI-PubMed.30990905.s5.e7" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e7" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e7" e2="DDI-PubMed.30990905.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e5" e2="DDI-PubMed.30990905.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30990905.s5.e5" e2="DDI-PubMed.30990905.s5.e6" /></sentence><sentence text=" Safety and tolerability were also assessed" /><sentence text=" Coadministration of letermovir with cyclosporine, tacrolimus, and sirolimus resulted in 1"><entity charOffset="21-31" id="DDI-PubMed.30990905.s7.e0" text="letermovir" /><entity charOffset="37-49" id="DDI-PubMed.30990905.s7.e1" text="cyclosporine" /><entity charOffset="51-61" id="DDI-PubMed.30990905.s7.e2" text="tacrolimus" /><entity charOffset="67-76" id="DDI-PubMed.30990905.s7.e3" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e0" e2="DDI-PubMed.30990905.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e0" e2="DDI-PubMed.30990905.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e0" e2="DDI-PubMed.30990905.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e0" e2="DDI-PubMed.30990905.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e1" e2="DDI-PubMed.30990905.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e1" e2="DDI-PubMed.30990905.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e1" e2="DDI-PubMed.30990905.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e2" e2="DDI-PubMed.30990905.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s7.e2" e2="DDI-PubMed.30990905.s7.e3" /></sentence><sentence text="7-, 2" /><sentence text="4-, and 3" /><sentence text="4-fold increases in area under the plasma concentration-time curve and 1" /><sentence text="1-, 1" /><sentence text="6-, and 2" /><sentence text="8-fold increases in maximum plasma concentration, respectively, of the immunosuppressants" /><sentence text=" Coadministration of letermovir and MMF had no meaningful effect on the PK of mycophenolic acid"><entity charOffset="78-95" id="DDI-PubMed.30990905.s14.e0" text="mycophenolic acid" /><entity charOffset="36-52" id="DDI-PubMed.30990905.s14.e1" text="MMF" /><pair ddi="false" e1="DDI-PubMed.30990905.s14.e1" e2="DDI-PubMed.30990905.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s14.e1" e2="DDI-PubMed.30990905.s14.e0" /></sentence><sentence text=" Coadministration with cyclosporine increased letermovir area under the plasma concentration-time curve by 2"><entity charOffset="23-35" id="DDI-PubMed.30990905.s15.e0" text="cyclosporine" /><entity charOffset="46-56" id="DDI-PubMed.30990905.s15.e1" text="letermovir" /><pair ddi="false" e1="DDI-PubMed.30990905.s15.e0" e2="DDI-PubMed.30990905.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30990905.s15.e0" e2="DDI-PubMed.30990905.s15.e1" /></sentence><sentence text="1-fold and maximum plasma concentration by 1" /><sentence text="5-fold, while coadministration with MMF did not meaningfully affect the PK of letermovir"><entity charOffset="36-45" id="DDI-PubMed.30990905.s17.e0" text="MMF" /></sentence><sentence text=" Given the increased exposures of cyclosporine, tacrolimus, and sirolimus, frequent monitoring of concentrations should be performed during administration and at discontinuation of letermovir, with dose adjustment as needed"><entity charOffset="34-46" id="DDI-PubMed.30990905.s18.e0" text="cyclosporine" /><entity charOffset="48-58" id="DDI-PubMed.30990905.s18.e1" text="tacrolimus" /><entity charOffset="64-73" id="DDI-PubMed.30990905.s18.e2" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30990905.s18.e0" e2="DDI-PubMed.30990905.s18.e0" /><pair ddi="false" e1="DDI-PubMed.30990905.s18.e0" e2="DDI-PubMed.30990905.s18.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s18.e0" e2="DDI-PubMed.30990905.s18.e2" /><pair ddi="false" e1="DDI-PubMed.30990905.s18.e1" e2="DDI-PubMed.30990905.s18.e1" /><pair ddi="false" e1="DDI-PubMed.30990905.s18.e1" e2="DDI-PubMed.30990905.s18.e2" /></sentence><sentence text=" These data support the reduction in clinical dosage of letermovir (to 240Â mg) upon coadministration with cyclosporine"><entity charOffset="106-118" id="DDI-PubMed.30990905.s19.e0" text="cyclosporine" /></sentence><sentence text="" /></document>